Holen Sie sich die Stockscreener-App
13.03
0.27%
0.045
Schlusskurs vom Vortag:
$12.98
Offen:
$13.25
24-Stunden-Volumen:
890.82K
Relative Volume:
0.41
Marktkapitalisierung:
$1.67B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.07M
KGV:
-44.91
EPS:
-0.29
Netto-Cashflow:
$-31.85M
1W Leistung:
-2.51%
1M Leistung:
+18.21%
6M Leistung:
+103.04%
1J Leistung:
+389.29%
1-Tages-Spanne:
$12.94
$13.45
1-Wochen-Bereich:
$12.85
$14.00
52-Wochen-Spanne:
$2.36
$14.00
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Vergleichen Sie TRVI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
13.02 | 1.66B | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.82 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.83 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.92 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-13 | Eingeleitet | Leerink Partners | Outperform |
| 2025-08-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-07-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Bestätigt | Needham | Buy |
| 2025-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-30 | Eingeleitet | Raymond James | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Trevi Therapeutics, Inc. $TRVI Shares Acquired by Vivo Capital LLC - MarketBeat
226,381 Shares in Trevi Therapeutics, Inc. $TRVI Bought by Prudential Financial Inc. - MarketBeat
Affinity Asset Advisors LLC Raises Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics appoints David Hastings as chief financial officer By Investing.com - Investing.com Nigeria
Trevi Therapeutics, Inc. Announces Appointment of David Hastings as Chief Financial Officer, Effective January 6, 2026 - marketscreener.com
Trevi Therapeutics, Inc. Announces the Hiring of David Hastings to Serve as the Company?s Principal Financial Officer, Effective January 6, 2026 - marketscreener.com
New Haven biotech names new CFO - Hartford Business Journal
Trevi Therapeutics Appoints New Chief Financial Officer - TipRanks
Trevi Therapeutics appoints David Hastings as chief financial officer - Investing.com
Trevi Therapeutics, Inc. $TRVI Shares Purchased by Geode Capital Management LLC - MarketBeat
Trevi Therapeutics appoints David Hastings as new CFO By Investing.com - Investing.com Nigeria
Trevi Therapeutics Taps David Hastings as CFO - Contract Pharma
Trevi Therapeutics appoints David Hastings as new CFO - Investing.com India
Trevi Therapeutics, Inc. $TRVI Shares Purchased by Panagora Asset Management Inc. - MarketBeat
Trevi Therapeutics Names David Hastings CFO - marketscreener.com
Trevi Therapeutics announces appointment of David Hastings as chief financial officer - marketscreener.com
Trevi Therapeutics Announces Appointment Of David Hastings As Chief Financial Officer - TradingView
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer - PR Newswire
Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond - Seeking Alpha
Trevi Therapeutics stock hits all-time high at 13.92 USD By Investing.com - Investing.com Canada
Trevi Therapeutics stock hits all-time high at 13.92 USD - Investing.com India
Trevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month HighWhat's Next? - MarketBeat
Trevi Therapeutics Draws Interest As Clinical Programs Move Forward - Kalkine Media
Trevi Therapeutics (TRVI) Rises on Takeover Speculation - GuruFocus
Trevi Therapeutics edges higher amid takeover speculation - MSN
Trevi Therapeutics edges higher amid takeover speculation (TRVI:NASDAQ) - Seeking Alpha
Trevi Therapeutics (TRVI) Stock Analysis Report | Financials & Insights - Benzinga
Jefferies Financial Group Inc. Makes New Investment in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Inc Strengthens Strategy For Clinical Design - Kalkine Media
Tejara Capital Ltd Purchases 146,879 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Sets New 52-Week HighStill a Buy? - MarketBeat
Stocks of Trevi Therapeutics Inc (TRVI) are poised to climb above their peers - Setenews
Trevi Therapeutics stock hits all-time high at 12.31 USD By Investing.com - Investing.com India
Trevi Therapeutics stock hits all-time high at 12.31 USD - Investing.com
AXQ Capital LP Invests $227,000 in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics’ Earnings Call Highlights Promising Outlook - MSN
The Bull Case For Trevi Therapeutics (TRVI) Could Change Following Narrowed Losses and New Shelf Registration - simplywall.st
Chronic Refractory Cough Market is Expected to Boom by 2034 Driven by Advancements in Treatment Options | DelveInsight - GlobeNewswire Inc.
MAI Capital Management Sells 537,497 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts - MarketBeat
Leerink Partnrs Has Bullish Outlook for TRVI FY2025 Earnings - MarketBeat
B. Riley Increases Earnings Estimates for Trevi Therapeutics - MarketBeat
B. Riley Predicts Increased Earnings for Trevi Therapeutics - Defense World
Trevi Therapeutics targets multiple phase III trial launches for chronic cough indications in 2026 as regulatory plans accelerate - MSN
Leerink Partners Maintains Trevi Therapeutics (TRVI) Outperform Recommendation - Nasdaq
TRVI's Price Target Raised by Leerink Partners to $16.00, Mainta - GuruFocus
What is B. Riley's Forecast for TRVI Q1 Earnings? - MarketBeat
Can Trevi Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Fed Impact & Stock Portfolio Risk Management - newser.com
Analyzing drawdowns of Trevi Therapeutics Inc. with statistical toolsBreakout Watch & Verified High Yield Trade Plans - newser.com
How resilient is Trevi Therapeutics Inc. stock in market downturns2025 Earnings Surprises & Trade Opportunity Analysis Reports - newser.com
Leerink Partners raises Trevi Therapeutics stock price target to $16 on Haduvio outlook By Investing.com - Investing.com South Africa
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):